An honest look at treating narrowed brain arteries — why aggressive medical therapy, not stenting, is now the first-choice treatment for most patients, and when stenting is still considered.
Intracranial artery stenosis is a narrowing of one of the arteries inside the skull, most often from atherosclerosis — the same fatty plaque build-up process that narrows arteries elsewhere in the body. When a brain artery narrows significantly, it reduces blood flow to the brain tissue it supplies and can also shed small clots that travel downstream, both of which can cause a stroke or a transient ischaemic attack (TIA, a "mini-stroke"). It's a genuinely important cause of stroke worldwide, disproportionately affecting people of Asian, Black, and Hispanic descent, and shares many of the same risk factors as atherosclerosis elsewhere — high blood pressure, diabetes, high cholesterol, and smoking.
Typically aspirin plus another agent, for a defined period.
Blood pressure and cholesterol managed with specific numerical targets.
Quitting smoking, managing diabetes, and regular exercise.
MRI or CT brain imaging alongside vascular imaging identifies and measures the narrowing.
A catheter is inserted at the groin or wrist under sedation.
A stent is deployed across the narrowing under live imaging guidance to restore blood flow.
Structured follow-up monitors for recurrent symptoms and stent patency.
This is an area where the evidence deserves an honest, direct answer rather than a sales pitch. For years, stenting was assumed to be a natural extension of the success seen with carotid and coronary stenting. The SAMMPRIS trial — a major randomised trial comparing stenting against aggressive medical therapy alone in symptomatic intracranial stenosis — found that aggressive medical therapy outperformed stenting, with a higher rate of stroke and complications in the stenting group within the trial's follow-up period. This result changed clinical practice significantly: stenting is no longer considered a routine first-line treatment for intracranial stenosis in the way it might be for other narrowed arteries.
Aggressive medical therapy means dual antiplatelet medication (typically aspirin plus another agent) for a defined period, tight control of blood pressure and cholesterol with specific numerical targets, and structured lifestyle changes — quitting smoking, managing diabetes, regular exercise. This isn't a lesser option chosen when stenting isn't available; the trial evidence shows it's genuinely the better first choice for most patients with intracranial stenosis.
Stenting hasn't disappeared from practice — it's been repositioned. It's generally considered for patients who have recurrent strokes or TIAs despite being on properly optimised medical therapy, meaning medical management has been given a genuine trial and has failed to control the risk. In this narrower, carefully selected group, more recent studies using newer-generation stents have shown improved technical success and safety profiles compared to the older devices used in the original landmark trials — reducing average stenosis substantially at the time of the procedure, with results largely maintained at follow-up imaging. This is why patient selection and operator experience both matter considerably in this specific procedure.
The procedure is done under sedation through a catheter inserted at the groin or wrist, navigated to the narrowed brain artery under live imaging guidance. A stent is deployed across the narrowing to hold the artery open and restore more normal blood flow. Because intracranial vessels are smaller and more delicate than the carotid or coronary arteries most stenting techniques were originally developed for, this requires specific neurointerventional experience — not simply an extension of stenting skills from elsewhere in the body.
Intracranial stenosis often first presents with a TIA or a completed stroke — sudden weakness, numbness, speech difficulty, or vision changes affecting one side of the body, depending on which artery and territory is involved. Some patients experience recurrent, similar episodes as the narrowing progressively limits blood flow further. Diagnosis typically starts with MRI or CT brain imaging alongside vascular imaging — CT angiography, MR angiography, or transcranial Doppler ultrasound — to identify and measure the degree of narrowing. Catheter angiography remains the most precise way to characterise the stenosis and, when stenting is being considered, to plan the procedure itself.
If you've been told you have intracranial artery stenosis, the most important first step is a genuine, sustained trial of medical therapy under specialist supervision — not immediate stenting. If symptoms recur despite that, a specialist evaluation can determine whether you fall into the group where stenting's benefit is more clearly established.
No — major trial evidence shows aggressive medical therapy alone outperforms stenting for most patients. Stenting is reserved for select patients whose symptoms recur despite optimal medical treatment.
Dual antiplatelet medication for a defined period, tight blood pressure and cholesterol control with specific targets, and lifestyle changes — smoking cessation, diabetes management, regular exercise. It's genuinely the better first-choice treatment, not a fallback.
When a patient has recurrent stroke or TIA symptoms despite being properly optimised on medical therapy — meaning medical management has had a real trial and hasn't controlled the risk on its own.
Recent studies using newer-generation devices have shown improved technical success and safety profiles in carefully selected patients compared with the older stents used in the original landmark trials, though this remains a procedure where patient selection matters greatly.
Book a consultation with Dr. Giragani to discuss the right treatment approach for your case.